Form 8-K - Current report:
SEC Accession No. 0001628280-23-000762
Filing Date
2023-01-09
Accepted
2023-01-09 16:10:28
Documents
13
Period of Report
2023-01-06
Items
Item 2.02: Results of Operations and Financial Condition

Document Format Files

Seq Description Document Type Size
1 8-K auph-20230106.htm   iXBRL 8-K 38037
2 EX-99.1 auph4qpreannounceprjanuary.htm EX-99.1 19440
  Complete submission text file 0001628280-23-000762.txt   199946

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT auph-20230106.xsd EX-101.SCH 1930
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT auph-20230106_lab.xml EX-101.LAB 23832
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT auph-20230106_pre.xml EX-101.PRE 12530
7 EXTRACTED XBRL INSTANCE DOCUMENT auph-20230106_htm.xml XML 10828
Mailing Address #1203-4464 MARKHAM STREET VICTORIA BC A1 V8Z 7X8
Business Address #1203-4464 MARKHAM STREET VICTORIA BC A1 V8Z 7X8 250-708-4272
Aurinia Pharmaceuticals Inc. (Filer) CIK: 0001600620 (see all company filings)

IRS No.: 000000000 | State of Incorp.: A0 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36421 | Film No.: 23518201
SIC: 2834 Pharmaceutical Preparations